STAAR Surgical reports Q1 2026 results
Net sales reached $93.5 million, net income was $5.2 million, and Adjusted EBITDA totaled $24.4 million.
See the latest news and media coverage for STAAR Surgical. We track all announcements, press releases, and industry mentions in real time, all in one place.
Implantable lens designer and manufacturer
staar.comLast updated
In short: STAAR Surgical reported strong Q1 2026 financial results and secured an expanded FDA approval for its EVO ICL lenses.
Net sales reached $93.5 million, net income was $5.2 million, and Adjusted EBITDA totaled $24.4 million.
The company expects net sales in excess of $90 million for Q1, driven by China and Americas, and anticipates improved adjusted EBITDA.
Net sales grew 18% in Q4 but declined 24% for the full year; net loss narrowed.
The milestone reflects a shift from laser-based vision correction to lens-based procedures, driven by regulatory and clinical progress.
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. See why STAA...
Staar Surgical Company’s future performance appears highly exposed to numerous external factors that management cannot fully anticipate or control. An investor reviewing its Form 10-K...
On May 14, 2026, Staar Surgical Co STAA shares rose 8.9% to $32.01, continuing a strong upward trend that has seen the stock increase by...
Staar Surgical (STAA) Analyst Rating Update On October 14, 2023, Wells Fargo maintained an Equal-Weight rating on Staar Surgical (STAA). The price target wa...
Track STAAR Surgical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to STAAR Surgical and other trending companies.